Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,197
archived clinical trials in
Atrial Fibrillation

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Milwaukee, WI
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Weston, WI
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Weston, WI
Click here to add this to my saved trials
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated:  6/27/2016
Research Site
mi
from
Bahía Blanca,
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated: 6/27/2016
Research Site
mi
from
Bahía Blanca,
Click here to add this to my saved trials
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Status: Enrolling
Updated:  12/15/2016
Beaumont Health System
mi
from
Royal Oak, MI
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Status: Enrolling
Updated: 12/15/2016
Beaumont Health System
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Cardiology Consultants Of Orange County Med. Group Inc
mi
from
Anaheim, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Cardiology Consultants Of Orange County Med. Group Inc
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Oracle Clinical Research, Inc.
mi
from
Anaheim, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Oracle Clinical Research, Inc.
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
WCCT Global, LLC
mi
from
Costa Mesa, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
WCCT Global, LLC
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Long Beach VA Medical Center
mi
from
Long Beach, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Long Beach VA Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Spectrum Clinical Research
mi
from
Moreno Valley, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Spectrum Clinical Research
mi
from
Moreno Valley, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Chase Medical Research, LLC
mi
from
Waterbury, CT
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
ALL Medical Research, LLC
mi
from
Cooper City, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
ALL Medical Research, LLC
mi
from
Cooper City, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
The Cardiac And Vascular Institute Research Foundation, Llc
mi
from
Gainesville, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
The Cardiac And Vascular Institute Research Foundation, Llc
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Acrc Cardiology
mi
from
Lake Worth, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Acrc Cardiology
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
The Heart Institute at Largo
mi
from
Largo, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
The Heart Institute at Largo
mi
from
Largo, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Columbus Regional Research Institute
mi
from
Columbus, GA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Columbus Regional Research Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Community Clinical Research Center
mi
from
Anderson, IN
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Community Clinical Research Center
mi
from
Anderson, IN
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Midwest Heart & Vascular Specialists, LLC
mi
from
Overland Park, KA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Midwest Heart & Vascular Specialists, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Cambridge Medical Trials
mi
from
Alexandria, LA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Cambridge Medical Trials
mi
from
Alexandria, LA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Castlerock Clinical Research Consultants, LLC
mi
from
Tulsa, OK
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Castlerock Clinical Research Consultants, LLC
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Capital Area Research
mi
from
Camp Hill, PA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Capital Area Research
mi
from
Camp Hill, PA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Tennessee Center for Clinical Trials
mi
from
Tullahoma, TN
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Tennessee Center for Clinical Trials
mi
from
Tullahoma, TN
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Texas Cardiac Arrhythmia Research Foundation
mi
from
Austin, TX
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Texas Cardiac Arrhythmia Research Foundation
mi
from
Austin, TX
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Utah Cardiology PC
mi
from
Layton, UT
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Utah Cardiology PC
mi
from
Layton, UT
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Local Institution
mi
from
Edmonton,
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Local Institution
mi
from
Edmonton,
Click here to add this to my saved trials
Use of Electronic Personal Health Records to Improve Medication Adherence
The Use of Electronic Personal Health Records to Improve Medication Adherence Among Non-Valvular Atrial Fibrillation Patients: A Pilot Study
Status: Enrolling
Updated:  1/10/2017
Parkview Research Center; Parkview Health
mi
from
Fort Wayne, IN
Use of Electronic Personal Health Records to Improve Medication Adherence
The Use of Electronic Personal Health Records to Improve Medication Adherence Among Non-Valvular Atrial Fibrillation Patients: A Pilot Study
Status: Enrolling
Updated: 1/10/2017
Parkview Research Center; Parkview Health
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Mobile, AL
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Troy, MI
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Troy, MI
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Akron, OH
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Camp Hill, PA
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Houston, TX
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Walla Walla, WA
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Capital Federal,
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Capital Federal,
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Birmingham, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Dothan, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Huntsville, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Mobile, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Montgomery, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Montgomery, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Pell City, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Pell City, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Tuscaloosa, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Cottonwood, AZ
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Cottonwood, AZ
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Tucson, AZ
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Fort Smith, AR
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Carlsbad, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Carmichael, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Carmichael, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Corona, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Corona, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Laguna Hills, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Long Beach, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials